Clinical trials: Urinary Bladder Neoplasm
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00792025
- Testing
- sunitinib malate
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Institut Curie
Transitional Cell Bladder Cancer, Cystectomy
Radical Cystectomy Versus Tri-Modal Therapy for Treatment of cT2N0M0 Urinary Bladder Transitional Cell Carcinoma
the aim of this study is to compare the oncological outcome of trimodal therapy with bladder preservation using maximal resection with chemoradiation versus the standard radical cystectomy for muscle invasive transitional cell…
- Conditions
- Transitional Cell Bladder Cancer, Cystectomy, Radiation
- Trial name
- NCT07043790
- Testing
- Radical cystectomy with pelvic lymphadenectomy, Trimodal therapy
- Where
- Egypt
- Volunteers
- 73 people
- Sponsor
- Ain Shams University
Prostate Cancer, Renal Cell Carcinoma
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid.
- Conditions
- Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02080650
- Testing
- Mesenchymal-marker based ferrofluid (c-MET), Epithelial cell adhesion molecule (EpCAM) ferrofluid
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
Over-Active Bladder
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.
- Trial name
- NCT01777217
- Testing
- Solifenacin succinate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Advanced Research Network
Bladder Cancer, Carcinoma, Transitional Cell
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
Primary Objective: To analyse time to tumor progression in patients cystectomized for locally advanced transitional cell carcinoma (TCC) of the bladder, who are not suitable for cisplatin-based chemotherapy (i.e.
- Trial name
- NCT00146276
- Testing
- gemcitabine
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Association of Urologic Oncology (AUO)
Bladder Cancer Stage I
Can Second Resection for pT1 Bladder Cancer be Avoided After Initial En-Bloc Resection With Negative Safety Margins
The goal of this [ Can second resection for pT1 bladder carcinoma be safely avoided after initial En-Bloc Resection with negative vertical and horizontal safety margins ? is to assess the impact of avoiding re TUR on Recurrence…
- Trial name
- NCT05969964
- Testing
- Avoid second resection after initial complete resection
- Where
- Egypt
- Volunteers
- 370 people
- Sponsor
- Mansoura University
Malignant Melanoma, Metastatic, Non Small Cell Lung Cancer Metastatic
Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
The primary objective is to assess tolerability and safety of a personalized neo-antigen vaccine containing up to 15 peptides derived from somatic mutation of the individual patient's cancer, with CAF09b as adjuvant.
- Conditions
- Malignant Melanoma, Metastatic, Non Small Cell Lung Cancer Metastatic, Bladder Urothelial Carcinoma, Metastatic
- Trial name
- NeoPepVac (NCT03715985)
- Testing
- EVAX-01-CAF09b
- Where
- 2 sites in Denmark
- Volunteers
- 12 people
- Sponsor
- Herlev Hospital
Bladder Cancer, Non-muscle Invasive
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids
From patients with intermediate risk non-muscle invasive bladder cancer tumor (NMIBC) specimens will be harvested during transurethral resection. Fresh specimens will be cultured as patient derived organoids (PDO). After approx.
- Trial name
- GAIN-INST (NCT05024734)
- Testing
- Epirubicin, Mitomycin, Gemcitabine
- Where
- Switzerland
- Volunteers
- 31 people
- Sponsor
- Roland Seiler-Blarer
Upper Urinary Tract Urothelial Carcinoma
The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract
This is a study looking at how patients with a rare type of cancer in the pelvis and ureter of the kidney - called upper urinary tract urothelial carcinoma (UTUC) - is currently treated.
- Trial name
- EuroCUT (NCT07077447)
- Testing
- Kidney sparing surgery for high-risk upper urinary tract urothelial carcinoma
- Where
- 5 sites in Denmark, Norway
- Volunteers
- 2,500 people
- Sponsor
- Zealand University Hospital
Bladder Cancers
Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)
The purpose of the study is the identification of chromosomal aberrations in urine samples. The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of UroVysion…
- Trial name
- NCT01264744
- Where
- 3 sites in United States
- Volunteers
- 174 people
- Sponsor
- Applied Spectral Imaging Ltd.
Pancreatic Cancer, Colon Cancer
Cancer Loyalty Card Study 2 (CLOCS-2)
Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early.
- Conditions
- Pancreatic Cancer, Colon Cancer, Oesophageal Cancer, Stomach Cancer
- Trial name
- (CLOCS-2) (NCT06447064)
- Testing
- Cases & Controls
- Where
- United Kingdom
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Bladder Cancer
Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup
Bacillus Calmette-Guerin (BCG) has been extensively utilized in intravesical instillation therapy for patients with medium to high risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumor…
- Trial name
- NCT06153849
- Testing
- urine sample collection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changhai Hospital
Bladder Cancer, CLE
Confocal Laser Endomicroscopy During TransUrethral Resection for Improving BC Diagnosis and Treatment
A prospective monocenter diagnostic accuracy study of Confocal Laser Endomicroscopy (CLE) for Bladder Cancer(BC) to assess two primary objectives: 1.
- Trial name
- CLETUR (NCT05273593)
- Testing
- Confocal Laser Endomicroscopy (CLE)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Non Muscle Invasive Bladder Cancer
The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder Cancer
Bladder cancer is one of the most common malignancies worldwide and represents a major global health burden. According to the GLOBOCAN 2022 estimates, approximately 614,298 new cases and 220,596 deaths from bladder cancer were…
- Trial name
- NCT07873333
- Testing
- Definitive radiotherapy, BCG, Concurrent chemotherapy
- Volunteers
- 70 people
- Sponsor
- Assiut University
Bladder Cancer
Bladder Cancer Case Control Study of Arsenic in Water
This study is examining the relationship between ingested arsenic and bladder cancer in two areas of California where a large percentage of the population was exposed to drinking water containing arsenic at low to moderate levels.
- Trial name
- NCT00011518
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Non-muscle Invasive Bladder Cancer
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 combined with gemcitabine for patients who have BCG failure (defined as refractory, relapsing or intolerant), non-muscle invasive bladder…
- Trial name
- NCT01625260
- Testing
- ALT-801, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Altor BioScience
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Urinary Bladder Neoplasms
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
Nowadays, Immune Checkpoint Inhibitor (ICI) has become one of the new drugs for the treatment of advanced uroepithelial carcinoma.
- Trial name
- CBPTMI (NCT05445648)
- Testing
- Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Bladder Cancer
Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer
Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy. Postoperative survival stratification based on radiomics and deep learning may be useful for treatment decisions to improve prognosis.
- Trial name
- NCT06092450
- Testing
- develop and validate a deep learning radiomics model based on preoperative enhanced CT image
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Bladder Cancer
Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)
Trimodal therapy (TMT) consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy is a therapeutic alternative in patients with Muscle-Infiltrating Bladder Cancer who are inoperable or…
- Trial name
- BLADAPT (NCT07043543)
- Testing
- Adaptive radiotherapy, standard radiotherapy
- Where
- 11 sites in France
- Volunteers
- 120 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle